Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Over the last 12 months, insiders at Laboratory Corporation of America Holdings have bought $0 and sold $14.23M worth of Laboratory Corporation of America Holdings stock.
On average, over the past 5 years, insiders at Laboratory Corporation of America Holdings have bought $691,649 and sold $16.8M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 44 shares for transaction amount of $10,251 was made by Caveney Brian J (EVP, President of Diagnostics) on 2022‑09‑07.
2024-05-14 | Sale | van der Vaart Sandra D | EVP, Chief Legal Officer | 2,000 0.0024% | $210.83 | $421,655 | -5.76% | |
2024-05-02 | Sale | ANDERSON KERRII B | director | 250 0.0003% | $200.10 | $50,025 | +0.49% | |
2024-04-30 | Sale | ANDERSON KERRII B | director | 250 0.0003% | $204.13 | $51,034 | -0.08% | |
2024-04-29 | Sale | Wilkinson Peter J | SVP, Chief Accounting Officer | 2,439 0.0029% | $204.33 | $498,358 | -1.47% | |
2024-04-01 | Sale | Schroeder Mark S | EVP, Pres Diagnostics & COO | 6,477 0.0077% | $217.29 | $1.41M | -6.81% | |
2024-04-01 | Sale | Summy Amy B. | EVP, Chief Marketing Officer | 3,500 0.0042% | $217.29 | $760,515 | -6.81% | |
2024-03-28 | Sale | van der Vaart Sandra D | EVP, Chief Legal Officer | 3,553 0.0042% | $216.74 | $770,077 | -7.64% | |
2024-03-07 | Sale | Schroeder Mark S | EVP, Pres Diagnostics & COO | 5,048 0.006% | $218.45 | $1.1M | -5.60% | |
2024-03-07 | Sale | Summy Amy B. | EVP, Chief Marketing Officer | 227 0.0003% | $218.45 | $49,588 | -5.60% | |
2024-02-21 | Sale | EISENBERG GLENN A | Chief Financial Officer, EVP | 34,504 0.0403% | $215.97 | $7.45M | -4.77% | |
2024-02-21 | Sale | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | 500 0.0006% | $215.49 | $107,745 | -4.77% | |
2024-02-13 | Sale | van der Vaart Sandra D | EVP, Chief Legal Officer | 237 0.0003% | $226.45 | $53,669 | -6.89% | |
2024-02-08 | Sale | van der Vaart Sandra D | EVP, Chief Legal Officer | 259 0.0003% | $222.06 | $57,514 | -6.65% | |
2024-02-05 | Sale | van der Vaart Sandra D | EVP, Chief Legal Officer | 193 0.0002% | $220.57 | $42,570 | -4.84% | |
2023-11-16 | Sale | Wilkinson Peter J | SVP, Chief Accounting Officer | 1,384 0.0016% | $210.71 | $291,627 | +1.55% | |
2023-08-08 | Sale | ANDERSON KERRII B | director | 5,000 0.0056% | $211.57 | $1.06M | -1.50% | |
2023-06-29 | Sale | van der Vaart Sandra D | EVP, Chief Legal Officer | 212 0.0003% | $240.00 | $50,880 | +2.32% | |
2023-05-19 | Sale | Kirchgraber Paul R | CEO, Covance Drug Development | 4,300 0.0049% | $216.91 | $932,707 | +13.45% | |
2023-05-18 | Sale | Schroeder Mark S | EVP, Pres Diagnostics & COO | 1,500 0.0017% | $216.77 | $325,155 | +13.83% | |
2023-03-31 | Sale | Schroeder Mark S | EVP, President-Diagnostics Lab | 3,897 0.0043% | $225.81 | $879,982 | +7.14% |
EISENBERG GLENN A | Chief Financial Officer, EVP | 23595 0.032% | $203.24 | 0 | 10 | |
ANDERSON KERRII B | director | 15722 0.018% | $203.24 | 0 | 8 | |
van der Vaart Sandra D | EVP, Chief Legal Officer | 5637 0.009% | $203.24 | 0 | 22 | |
Schroeder Mark S | EVP, Pres Diagnostics & COO | 5036 0.0079% | $203.24 | 0 | 18 | |
DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | 3401 0.004% | $203.24 | 0 | 1 | |
Wilkinson Peter J | SVP, Chief Accounting Officer | 2087 0.0025% | $203.24 | 0 | 5 | |
Summy Amy B. | EVP, Chief Marketing Officer | 3975 0.0003% | $203.24 | 0 | 3 | |
KING DAVID P | director | 312554 0.3681% | $203.24 | 0 | 38 | |
NOVAK RICHARD L | EVP, Strategic Planning | 62270 0.0733% | $203.24 | 0 | 22 | |
ELINGBURG WESLEY R | EVP & Chief Financial Officer | 56244 0.0662% | $203.24 | 0 | 19 | |
STARK STEVAN R | Executive Vice President | 49730 0.0586% | $203.24 | 0 | 6 | |
MAC MAHON THOMAS P | director | 32297 0.038% | $203.24 | 0 | 27 | |
HARDISON DON M | EVP, COO | 23776 0.028% | $203.24 | 0 | 2 | |
EBERTS F SAMUEL III | Chief Legal Officer, Secretary | 23694 0.0279% | $203.24 | 0 | 13 | |
Boyle James T. Jr. | EVP,CEO of LabCorp Diagnostics | 23454 0.0276% | $203.24 | 0 | 16 | |
LAI GOLDMAN MYLA | EVP & Chief Medical Officer | 22660 0.0267% | $203.24 | 0 | 30 | |
Walton Andrew Scott | EVP | 22298 0.0263% | $203.24 | 0 | 9 | |
HAAS WILLIAM | EVP, Esoterix Business | 20401 0.024% | $203.24 | 0 | 7 | |
Hayes William B | Chief Financial Officer, EVP | 19400 0.0229% | $203.24 | 0 | 32 | |
LANE WENDY E | director | 17395 0.0205% | $203.24 | 1 | 8 | +3.62% |
SMITH BRADFORD T | director | 16030 0.0189% | $203.24 | 0 | 40 | |
BELINGARD JEAN-LUC | director | 15569 0.0183% | $203.24 | 0 | 11 | |
MITTELSTAEDT ROBERT E JR | director | 15209 0.0179% | $203.24 | 0 | 12 | |
Caveney Brian J | EVP, President of Diagnostics | 14282 0.0168% | $203.24 | 2 | 0 | <0.0001% |
Kirchgraber Paul R | CEO, Covance Drug Development | 12946 0.0152% | $203.24 | 0 | 4 | |
Cook Woodrow L | EVP, Eastern Operations | 12535 0.0148% | $203.24 | 0 | 6 | |
WEIKEL M KEITH | director | 12365 0.0146% | $203.24 | 0 | 2 | |
WALLACE ANDREW G | director | 11600 0.0137% | $203.24 | 0 | 6 | |
NEUPERT PETER M | director | 10254 0.0121% | $203.24 | 1 | 0 | <0.0001% |
Miller Benjamin R | EVP, Sales & Marketing | 10135 0.0119% | $203.24 | 0 | 12 | |
Dodson Edward T | Principal Accounting Officer | 9113 0.0107% | $203.24 | 0 | 3 | |
Fonseca Lidia | Chief Information Officer | 7813 0.0092% | $203.24 | 0 | 4 | |
Williams R Sanders | 6431 0.0076% | $203.24 | 0 | 14 | ||
Gilliland Dwight Gary | director | 6252 0.0074% | $203.24 | 0 | 3 | |
BERBERIAN LANCE | SVP, Chief Information Officer | 6097 0.0072% | $203.24 | 0 | 3 | |
Conrad Andrew J | EVP, Chief Scientific Officer | 6100 0.0072% | $203.24 | 1 | 1 | +19.38% |
Schechter Adam H | director | 6034 0.0071% | $203.24 | 0 | 1 | |
Brecher Mark E | CMO, LabCorp Diagnostics | 5511 0.0065% | $203.24 | 0 | 8 | |
Uthgenannt Lisa J | Chief Human Resources Officer | 4660 0.0055% | $203.24 | 0 | 6 | |
Gary M. Huff | CEO, LabCorp Diagnostics | 1610 0.0019% | $203.24 | 0 | 1 | |
Watson Craig M | director | 1288 0.0015% | $203.24 | 1 | 6 | +22.07% |
Seltz Judith C | EVP, CHRO | 580 0.0007% | $203.24 | 2 | 0 | +9.05% |
HERRING JOSEPH L | CEO of Covance Drug Division | 0 0% | $203.24 | 0 | 1 |
The Vanguard Group | $2.11B | 11.43 | 9.64M | -1.12% | -$23.87M | 0.04 | |
BlackRock | $2.06B | 11.19 | 9.43M | -10.06% | -$230.42M | 0.05 | |
State Street | $804.73M | 4.37 | 3.68M | -2.3% | -$18.93M | 0.04 | |
Wellington Management Company | $487.81M | 2.65 | 2.23M | -0.67% | -$3.31M | 0.08 | |
Geode Capital Management | $419.88M | 2.29 | 1.93M | +3.03% | +$12.36M | 0.04 | |
JPMorgan Chase | $378.44M | 2.06 | 1.73M | +14.62% | +$48.28M | 0.03 | |
LAZARD ASSET MANAGEMENT LLC | $371.63M | 2.02 | 1.7M | -6.58% | -$26.18M | 0.49 | |
Allspring Global Investments | $352.56M | 1.92 | 1.61M | +58.8% | +$130.55M | 0.55 | |
Diamond Hill Investment Group Inc | $339.58M | 1.84 | 1.55M | +9.17% | +$28.53M | 1.39 | |
Dimensional Fund Advisors | $302.38M | 1.64 | 1.38M | -4.31% | -$13.61M | 0.08 | |
Ubs Asset Management Americas Inc | $292.09M | 1.59 | 1.34M | +12.03% | +$31.37M | 0.1 | |
Morgan Stanley | $282.82M | 1.54 | 1.29M | -33.07% | -$139.72M | 0.02 | |
Veritas Investment Partners Uk Ltd | $256.86M | 1.4 | 1.18M | +3.15% | +$7.83M | 5.04 | |
Northern Trust | $245.87M | 1.34 | 1.13M | -3.25% | -$8.25M | 0.04 | |
Fidelity Investments | $239.78M | 1.3 | 1.1M | -2.9% | -$7.17M | 0.02 | |
Invesco | $239.25M | 1.3 | 1.1M | -3.43% | -$8.5M | 0.05 | |
Bank of America | $187.06M | 1.02 | 856,276 | -32.08% | -$88.35M | 0.02 | |
Thrivent Financial For Lutherans | $186.35M | 1.01 | 853,015 | +9.48% | +$16.13M | 0.39 | |
Nuveen | $176.92M | 0.96 | 809,895 | -12.02% | -$24.17M | 0.05 | |
Legal & General | $168.29M | 0.91 | 770,367 | -3.26% | -$5.67M | 0.04 | |
Lord Abbett | $161.89M | 0.88 | 741,069 | +2.4% | +$3.8M | 0.56 | |
American Century Investments | $160.69M | 0.87 | 735,542 | -13.83% | -$25.79M | 0.1 | |
Cooke & Bieler, L.P. | $159.94M | 0.87 | 732,131 | +8.89% | +$13.06M | 1.48 | |
BNY Mellon | $149.63M | 0.81 | 684,945 | -4.95% | -$7.79M | 0.03 | |
Nordea Investment Management Ab | $141.05M | 0.77 | 649,382 | +23.67% | +$26.99M | 0.17 | |
Southpoint Capital Advisors Lp | $136.54M | 0.74 | 625,000 | -30.56% | -$60.08M | 2.7 | |
BECK MACK + OLIVER | $129.9M | 0.71 | 594,595 | +8.26% | +$9.91M | 2.63 | |
Mondrian Investment Partners Limited | $129.12M | 0.7 | 591,056 | +0.94% | +$1.2M | 1.77 | |
Stifel | $127.39M | 0.69 | 583,145 | +2.27% | +$2.83M | 0.15 | |
Ariel Investments | $118.97M | 0.65 | 544,574 | -1.13% | -$1.36M | 1.17 | |
Charles Schwab | $114.27M | 0.62 | 523,091 | +0.96% | +$1.08M | 0.03 | |
Barclays | $105.36M | 0.57 | 482,279 | +44.69% | +$32.54M | 0.05 | |
Massachusetts Financial Services Co Ma | $104.1M | 0.57 | 476,511 | -0.68% | -$714,364.21 | 0.03 | |
UBS | $102.7M | 0.56 | 470,123 | +16.42% | +$14.48M | 0.03 | |
Prudential Financial | $97.81M | 0.53 | 447,747 | +530.2% | +$82.29M | 0.14 | |
CalPERS | $97.26M | 0.53 | 445,204 | -1.6% | -$1.58M | 0.07 | |
AllianceBernstein | $90.03M | 0.49 | 412,124 | -69.06% | -$200.94M | 0.03 | |
Hotchkis & Wiley Capital Management | $86.68M | 0.47 | 396,767 | +3,533.07% | +$84.29M | 0.29 | |
Brandes Investment Partners | $86.11M | 0.47 | 394,156 | +17.96% | +$13.11M | 1.11 | |
Fil Ltd | $85.26M | 0.46 | 390,291 | -0.67% | -$578,700.54 | 0.08 | |
Madison Asset Management LLC | $85.16M | 0.46 | 389,839 | +13.75% | +$10.3M | 1.08 | |
Citadel Advisors LLC | $76.84M | 0.42 | 351,724 | -28.95% | -$31.31M | 0.05 | |
Franklin Templeton Investments | $75.44M | 0.41 | 345,331 | -1.5% | -$1.14M | 0.02 | |
Spears Abacus Advisors LLC | $74.9M | 0.41 | 342,871 | +6,689.52% | +$73.8M | 1.52 | |
Envestnet Asset Management Inc | $73.59M | 0.4 | 336,845 | -13.91% | -$11.89M | 0.03 | |
EARNEST Partners | $72.4M | 0.39 | 331,390 | +25.98% | +$14.93M | 0.33 | |
TSW (Thompson, Siegel & Walmsley LLC) | $72.25M | 0.39 | 330,706 | +32.6% | +$17.76M | 1.14 | |
Royal Bank of Canada | $70.44M | 0.38 | 322,461 | +4.25% | +$2.87M | 0.02 | |
Goldman Sachs | $70.58M | 0.38 | 323,074 | +30.87% | +$16.65M | 0.01 | |
Wells Fargo | $68.67M | 0.37 | 314,349 | -2.87% | -$2.03M | 0.02 |